Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
200 hedge funds and large institutions have $2.73B invested in Cymabay Therapeutics in 2023 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 79 increasing their positions, 60 reducing their positions, and 33 closing their positions.
312% more call options, than puts
Call options by funds: $84.7M | Put options by funds: $20.6M
69% more capital invested
Capital invested by funds: $1.61B → $2.73B (+$1.12B)
39% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 33
32% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 60
6% more funds holding
Funds holding: 189 → 200 (+11)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$45.6M |
| 2 |
BlackRock
New York
|
+$32.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.6M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$25.1M |
| 5 |
Morgan Stanley
New York
|
+$25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$36.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$26.7M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$26.6M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$25M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.3M |
CBAY Hedge Fund Activity: Q4 2023 in Review
200 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2023, worth a combined $2.73B — up 69% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new CBAY positions and 33 closed out — a net gain of 13 holders — while 79 added to existing stakes and 60 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $45.6M. The largest seller was Cormorant Asset Management, cutting an estimated $36.5M.
- 200 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2023, up from 189 in Q3 2023.
- Funds reported $2.73B of Cymabay Therapeutics stock for Q4 2023, up 69% quarter-over-quarter.
- 46 funds opened new Cymabay Therapeutics positions in Q4 2023 and 33 closed out, a net change of +13 holders.
- The largest Cymabay Therapeutics buyer in Q4 2023 was T. Rowe Price Associates, an estimated $45.6M added.
- The largest Cymabay Therapeutics seller in Q4 2023 was Cormorant Asset Management, an estimated $36.5M sold.
Based on aggregated 13F filings for Q4 2023.